TSX runs higher on rate cut expectations
Ecor1 Capital, a ten-percent owner of Adaptimmune Therapeutics PLC (NASDAQ:ADAP), has sold 64,339,538 ordinary shares of the company between July 28 and July 30. The sales amounted to $6.89 million, with prices ranging from $0.1012 to $0.1125. The transactions come as the stock trades near its 52-week low, having declined over 92% in the past year, with the company’s market cap now at $27.8 million.
On July 28, Ecor1 Capital sold 33,931,740 shares at a weighted average price of $0.1125 per share.
Following this, on July 29, the firm sold 2,687,460 shares at $0.1012 per share.
The sales concluded on July 30, with 27,433,338 shares sold at $0.1021 per share.
Following these transactions, Ecor1 Capital now owns 100,371,882 ordinary shares of Adaptimmune Therapeutics PLC. InvestingPro analysis reveals the company is rapidly burning through cash, with 17 additional key insights available to subscribers.
In other recent news, Adaptimmune Therapeutics announced the sale of its cell therapy assets, including the marketed TECELRA therapy and pipeline candidates, to US WorldMeds for $55 million in cash, with the potential for an additional $30 million in milestone payments. This transaction is expected to close by the end of the week. Following this announcement, H.C. Wainwright downgraded Adaptimmune’s stock rating from Buy to Neutral. Mizuho (NYSE:MFG) also downgraded the company’s stock from Outperform to Neutral, citing concerns about financial sustainability despite noting the initial success of the US commercial launch of Tecelra. The downgrade from Mizuho included a reduction in the price target from $1.50 to $0.50. Additionally, Context Therapeutics has appointed Dr. Karen Chagin as its new Chief Medical (TASE:BLWV) Officer, effective June 9, 2025. Dr. Chagin previously played a significant role at Adaptimmune in the approval of the TECELRA therapy. Her expertise in T cell therapies is expected to advance Context Therapeutics’ development efforts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.